0DPB'un PE Oranı emsallerine kıyasla nasıldır?

0DPB is good value based on its Price-To-Earnings Ratio (24x) compared to the peer average (71.4x).

0DPB'nin PE Oranı, European Biotechs Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

0DPB is good value based on its Price-To-Earnings Ratio (24x) compared to the European Biotechs industry average (24.7x).

0DPB'nin PE Oranı, Adil PE Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PE Oranıdır.

0DPB is expensive based on its Price-To-Earnings Ratio (24x) compared to the estimated Fair Price-To-Earnings Ratio (21.5x).

Gelecekteki nakit akışlarına bakıldığında 0DPB 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

0DPB (DKK213.8) is trading below our estimate of [[fair value]] (DKK1163.9)

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Bavarian Nordic (LSE:0DPB) - Hisse Senedi Fiyatı, Haberler ve Analizler

0DPB Stoklara Genel Bakış

Bavarian Nordic A/S hayat kurtaran aşılar geliştirmekte, üretmekte ve ticarileştirmektedir.

Şirket hakkında

0DPB temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	1/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Trading at 81.6% below our estimate of its fair value

Earnings are forecast to grow 9.19% per year

Risk Analizi

Profit margins (11.6%) are lower than last year (19.5%)

Large one-off items impacting financial results

Significant insider selling over the past 3 months

Volatile share price over the past 3 months compared to the UK market

Bavarian Nordic A/S Rakipler

Genus

LSE:GNS

UK£1.4b

Bioventix

AIM:BVXP

UK£190.5m

PeptiDream

TSE:4587

JP¥350.0b

Ergomed

AIM:ERGO

UK£701.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Bavarian Nordic
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	DKK 213.80
52 Haftanın En Yüksek Seviyesi	DKK 295.40
52 Haftanın En Düşük Seviyesi	DKK 134.65
Beta	1.54
11 Aylık Değişim	-4.59%
3 Aylık Değişim	13.73%
1 Yıllık Değişim	47.74%
33 Yıllık Değişim	-28.64%
5 Yıllık Değişim	32.34%
Halka arzdan bu yana değişim	-34.45%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0DPB	GB Biotechs	GB Pazar
7D	-2.1%	-0.3%	-1.3%
1Y	47.7%	-14.6%	8.9%

Getiri vs. Endüstri: 0DPB exceeded the UK Biotechs industry which returned -14.6% over the past year.

Getiri vs Piyasa: 0DPB exceeded the UK Market which returned 8.9% over the past year.

Fiyat Oynaklığı

Is 0DPB's price volatile compared to industry and market?
0DPB volatility
0DPB Average Weekly Movement	8.5%
Biotechs Industry Average Movement	8.3%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0DPB's share price has been volatile over the past 3 months compared to the UK market.

Zaman İçindeki Volatilite: 0DPB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1992	1,381	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S hayat kurtaran aşılar geliştirmekte, üretmekte ve ticarileştirmektedir. Şirket, IMVAMUNE, IMVANEX ve JYNNEOS adları altında çoğalmayan çiçek ve maymun çiçeği aşıları; Rabipur/RabAvert adı altında insan kullanımı için kuduz aşısı; Encepur adı altında kene kaynaklı ensefalit aşısı; ve MVABEA adı altında Ebola aşısı sunmaktadır. Ayrıca çiçek hastalığı tedavisi için MVA-BN; solunum sinsityal virüsü tedavisi için Faz III klinik çalışmalarında olan MVA-BN RSV; SARS-CoV-2 tedavisi için Faz III klinik çalışmasını tamamlayan ABNCoV2 geliştirmektedir.

Bavarian Nordic A/S Temel Bilgiler Özeti

Bavarian Nordic'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0DPB temel i̇stati̇sti̇kler
Piyasa değeri	DKK 16.97b
Kazançlar(TTM)	DKK 707.42m
Gelir(TTM)	DKK 6.08b

24.0x

F/K Oranı

2.8x

P/S Oranı

0DPB aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0DPB gelir tablosu (TTM)
Gelir	DKK 6.08b
Gelir Maliyeti	DKK 2.06b
Brüt Kâr	DKK 4.02b
Diğer Giderler	DKK 3.31b
Kazançlar	DKK 707.42m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 15, 2024

Hisse başına kazanç (EPS)	9.01
Brüt Marj	66.08%
Net Kâr Marjı	11.63%
Borç/Özkaynak Oranı	0.2%

0DPB uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0DPB Stoklara Genel Bakış

Ödüller

Risk Analizi

Bavarian Nordic A/S Rakipler

LSE:GNS

UK£1.4b

AIM:BVXP

UK£190.5m

TSE:4587

JP¥350.0b

AIM:ERGO

UK£701.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

CEO & President recently sold kr.24m worth of stock

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Second quarter 2024 earnings released

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Investor sentiment improves as stock rises 17%

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 16%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Now 21% undervalued

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023